- VIVUS Files Lawsuit Against Hetero for Infringement of Stendra Patents
- VIVUS Announces Date of 2016 Second Quarter Business Update and Financial Results Teleconference
- VIVUS Announces Favorable Markman Ruling in Qsymia(R) Patent Litigation
- VIVUS to Extend Return Date of STENDRA Commercial Rights
- Vivus Reports 2016 First Quarter Financial Results
A Growing Pipeline
VIVUS is developing innovative, next-generation therapies to address unmet needs in obesity, diabetes, sleep apnea and sexual health.